Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerReview of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancerOxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancerOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsThe efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data).Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patientsOxaliplatin: a review in the era of molecularly targeted therapyOxaliplatin: a review of evolving concepts.Metastatic colorectal cancer: systemic treatment in the new millennium.Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibilityThe clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation.Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.Quality of survival reporting in chemotherapy and surgery trials in patients with metastatic colorectal carcinoma.Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.Biological agents versus chemotherapy in the treatment of colorectal cancer.Impact of oxaliplatin-induced neuropathy in patients with colorectal cancer: a prospective evaluation at a single institution.Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patientsA 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.Hypersensitivity reactions related to oxaliplatin (OHP).Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancerOutcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical TrialMetastatic colorectal cancer-past, progress and futureMulticenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patientsTreatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.Oxaliplatin/5-FU without leucovorin chemotherapy in metastatic colorectal cancer.Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice?Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancerXELOX in colorectal cancer: a convenient option for the future?Treatment recommendations for metastatic colorectal cancer.Current and advancing treatments for metastatic colorectal cancer.Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.
P2860
Q26775949-1CE9E0EA-0BF1-4110-8E36-E696C0A10BCBQ28082382-58DB28A2-1CEF-40C0-94F4-115E8FC8207BQ28362939-0F662E09-ABE7-4D41-A1C0-78E012DDA788Q28364999-67806935-DA95-48E8-87F6-15FD388D4AB2Q30913489-06E0809B-61B1-4B4B-A9C5-D589836AC081Q33389163-76D887DE-EC2C-4CF6-BC79-71054C760329Q33400095-873D85C3-CABF-4E14-8466-8217E88BC91EQ33400418-23C8B6F2-2ED3-4074-8561-6CD6A4226FBEQ33722621-3ADD22C8-927A-4EA5-9D1A-E1CE6FBF3F3FQ33873552-BAD9D868-5087-4CB2-9B25-0C3B0F41A129Q34343973-B7B889AD-BD80-4604-A196-185C99EDC732Q34541434-0ED5F696-ACDB-45AC-AF9F-819DB597CD68Q34569008-95F30F33-A231-4BF5-9415-6A46AA80677BQ35148795-66BDE90F-792F-4292-9F27-0AB0056DDACEQ35584874-64725C9A-5BD9-4D98-94B3-F47A40FCFAE4Q36072532-DADCE5BE-B966-4194-BAD6-252E7DD9DDA4Q36187034-18307C1F-EAE5-449B-96B0-2AA5DCE271D4Q36375103-A1B8EBC9-B4AB-4395-BA4F-E9E179E66D01Q36384600-15BE36F1-5814-4F68-B541-101B94428E4DQ36391430-6A03B91F-2470-4C45-AFFC-D3CE1F04AC0FQ36521850-49B55660-117C-4D53-9CF7-FCD60D1F4B76Q36581502-0E7BBC64-119C-4940-9B69-C27C70C6E606Q36609769-48D82CDF-FEC5-466E-91CF-892A624615E2Q36616400-7E3076BF-4703-47CA-A9EC-D717A346D75AQ36645980-51F7372B-25A0-4A00-88F1-C2672F1ADC6CQ36671350-7AAAD776-59CF-46CD-9DF3-A0489A671A8EQ36692398-0C7CB965-6AC2-497E-865D-9AE3B88EAD87Q36822171-335B63FB-5413-4B1F-AB94-824F5A28167FQ36848090-9A979B58-8A58-49FC-A37A-48AC269F44CAQ36893806-D7A03E18-CCA5-421A-840C-100872F1FD0FQ37318017-78C3B961-DA0D-4E22-8303-ED08E09FA00AQ37410573-D05F1AF2-A502-4FB6-AAB5-022368710AF9Q37449141-AA01FEFE-911C-4C47-A9C6-04BC75CD8E55Q37466459-635F7F96-8452-4138-8C48-1618D7B8ACA8Q37476887-1E38B11B-B635-4B29-B175-9EABED4DB601Q37651586-3B6DD69B-8C80-4D05-93FF-5A43FB70A17BQ37839084-382427E1-129E-4A20-BDAE-AC20CF4B7A92Q37855303-CBF3CDA5-D530-495E-AD16-844338F1FACBQ38628257-43C462B2-FCB8-453B-A18F-522F9EDF56B6Q38799295-20D5E606-A606-4733-8F78-99E6680D4285
P2860
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@ast
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@en
Oxaliplatin added to the simpl ...... r metastatic colorectal cancer
@nl
type
label
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@ast
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@en
Oxaliplatin added to the simpl ...... r metastatic colorectal cancer
@nl
prefLabel
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@ast
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@en
Oxaliplatin added to the simpl ...... r metastatic colorectal cancer
@nl
P2093
P1476
Oxaliplatin added to the simpl ...... ctal cancer (FOLFOX6). GERCOR.
@en
P2093
Gilles-Amar V
Maindrault-Goebel F
Molitor JL
P304
P356
10.1016/S0959-8049(99)00149-5
P577
1999-09-01T00:00:00Z